US2005100605A1PendingUtilityA1

Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid

Assignee: LG LIFE SCIENCES LTD INCPriority: Apr 1, 1997Filed: Dec 17, 2004Published: May 12, 2005
Est. expiryApr 1, 2017(expired)· nominal 20-yr term from priority
A61K 9/1652
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm.

Claims

exact text as granted — not AI-modified
1 . A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm.  
     
     
         2 . The composition of  claim 1 , wherein the molecular weight of hyaluronic acid ranges from 1,000,000 to 3,200,000.  
     
     
         3 . The composition of  claim 1  further comprising a stabilizer.  
     
     
         4 . The composition of  claim 1 , wherein the average size of microparticle ranges from 1 to 10 μm.  
     
     
         5 . The composition of  claim 1 , wherein the drug is selected from the group consisting of human growth hormone, bovine somatotropin, porcine somatotropin, growth hormone releasing hormone, growth hormone releasing peptide, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, macrophage-colony stimulating factor, erythropoietin, bone morphogenetic protein, interferon, insulin, atriopeptin-III, monoclonal antibody, TNF, macrophage activating factor, interleukin, tumor denaturing factor, insulin-like growth factor, epidermal growth factor, tissue plasminogen activator, urokinase and a mixture thereof.  
     
     
         6 . The composition of  claim 1 , wherein the inorganic salt is selected from the group consisting of sodium, potassium, lithium, calcium, ammonium, magnesium, zinc, copper and cobalt salts of hyaluronic acid.  
     
     
         7 . The composition of  claim 3 , wherein the stabilizer is selected from the group consisting of a polysaccharide, protein, amino acid, lipid, fatty acid, polyethyleneglycol, inorganic salt, surfactant and a mixture thereof.  
     
     
         8 . An injection formulation comprising the sustained-release composition of  claim 1  dispersed in an injection medium.  
     
     
         9 . The injection formulation of  claim 8  further comprising a dispersant or preservative.  
     
     
         10 . The injection formulation of  claim 8 , wherein the injection medium is selected from the group consisting of a buffered aqueous solution, ethanol, propyleneglycol, polyethyleneglycol, vegetable oil, mineral oil, squalene, cod liver oil, mono-, di- and tri-glyceride and a mixture thereof.  
     
     
         11 . The injection formulation of  claim 10 , wherein the vegetable oil is selected from the group consisting of corn oil, olive oil, soy bean oil, safflower oil, cottonseed oil, peanut oil, sesame oil, coconut oil, castor oil and a mixture thereof.  
     
     
         12 . An aerosol formulation comprising the sustained-release composition of  claim 1.

Join the waitlist — get patent alerts

Track US2005100605A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.